David J. Grainger - Jul 1, 2022 Form 4 Insider Report for Centessa Pharmaceuticals plc (CNTA)

Role
Chief Innovation Officer
Signature
/s/ Marella Thorell, attorney-in-fact
Stock symbol
CNTA
Transactions as of
Jul 1, 2022
Transactions value $
$0
Form type
4
Date filed
7/6/2022, 06:16 PM
Previous filing
Feb 3, 2022
Next filing
Nov 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction CNTA Ordinary Shares Award $0 +100K +12.29% $0.00 914K Jul 1, 2022 Direct F1, F2
holding CNTA Ordinary Shares 27.5K Jul 1, 2022 See footnote F1, F3
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 The Ordinary Shares may be represented by American Depositary Shares, each of which currently represents one Ordinary Share.
F2 The shares reported in this transaction represent Restricted Share Units ("RSUs") issued under the Centessa Pharmaceuticals plc Amended and Restated 2021 Stock Option and Incentive Plan. Each RSU represents the contingent right to receive one Ordinary Share of the Issuer. The RSUs shall vest and be settled in 10 equal quarterly instalments with the first such quarterly vesting being on September 30, 2022.
F3 Held by RxCelerate Limited ("RxCelerate"). The Reporting Person is a member of the board of directors of RxCelerate. The Reporting Person disclaims Section 16 beneficial ownership of the securities held by RxCelerate, except to the extent of his pecuniary interest therein, if any, and this report shall not be deemed to be an admission that he has beneficial ownership of such shares for Section 16 or any other purpose.